Plasma levels of lidocaine during combined treatment with phenytoin and procainamide.
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008012:Lidocaine / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D009203:Myocardial Infarction / Q000188:drug therapy; D010672:Phenytoin / Q000494:pharmacology*; D011342:Procainamide / Q000494:pharmacology*; D012472:Salivation / Q000187:drug effects; D012640:Seizures / Q000139:chemically induced; D013050:Spectrometry, Fluorescence; D014839:Vomiting / Q000139:chemically induced
D010672:Phenytoin; D008012:Lidocaine; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D011342:Procainamide